ClinicalTrials.gg
WithdrawnNCT06712433CONCERTOUpdated Oct 26, 2026

Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)

A Phase 2 interventional study of 2% intranasal mupirocin ointment and 4% chlorhexidine gluconate body cleanser in Sarcoma,Soft Tissue, sponsored by Adam Olson. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Adam Olson · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
Per the PI, this study is not proceeding due to funding and insufficient support.
Updated Oct 26, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 242 under way, 4 of them phase 3. Sarcoma · United States.

Enrollment
772nd of 800
0 · median 35
Started
2026
with 37 others
Phase 2
310 of 958
30 open now
Registered
894th of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 772nd largest by enrollment of the 800 interventional ones that give a count, is one of 38 that started in 2026, is one of 310 in phase 2, and was the 894th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

This trial will investigate the combination of two low-cost, non-toxic strategies to assess whether they can reduce the risk of acute major wound complications in soft tissue sarcoma of the lower extremity. Intranasal mupirocin ointment twice daily and chlorhexidine body cleanser once daily for 5 days prior to radiation therapy and repeated for 5 days every 2 weeks during radiation therapy may significantly reduce the risk of acute radiation dermatitis. That, along with use of indocyanine green (ICG) angiography at the time of wound closure.

Read the detailed description

Strategies to reduce the risk of acute wound complications have historically been mostly unsuccessful. In soft tissue sarcomas, a prior study showed that the use of indocyanine green (ICG) angiography at the time of wound closure was associated with a reduction in wound dehiscence and infection when compared to historical controls. Cutaneous colonization of S. aureus has been implicated in severe cases of radiation dermatitis. Some known risk factors for acute major wound complications for patients with sarcomas are anatomic location in the lower extremity, preoperative radiation therapy, larger tumors, comorbidities (e.g., diabetes mellitus, tobacco usage, vascular disease, and obesity), tumors \<3mm from skin surface, and the development of grade ≥ 2 acute radiation dermatitis. Both large tumors and lower extremity location can increase the likelihood of seroma formation, which can act as a nidus for infection and subsequent wound complication. Rationale for this trial includes prior studies of treating patients with a bacterial decolonization (BD) protocol of intranasal mupirocin ointment twice daily and chlorhexidine body cleanser once daily for 5 days prior to RT and repeated for 5 days every 2 weeks during radiation therapy that show significantly reduced risk of acute radiation dermatitis.

03

Conditions studied

  • Sarcoma,Soft Tissue

Browse trials for

Keywords

  • bacterial decolonization (BD)
  • external beam radiotherapy (RT)
  • wide local excision (WLE)
  • intraoperative IICG angiography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (ECOG) performance status (PS) 0-2
  2. Newly diagnosed soft tissue sarcoma arising from the lower extremity (defined as the tumor center arising at the level of the iliac crest or below)
  3. Eligible for wide local excision
  4. Eligible for external beam radiation therapy
  5. Negative serum pregnancy test for women of \< 28 days prior to RT.
  6. signed and dated to participate in the study.
  7. Willingness and ability to comply

Exclusion criteria

Exclusion Criteria:

  1. Allergy to mupirocin and/or chlorhexidine
  2. Active dermatologic condition in RT field
  3. Tumor size > 32cm
  4. Prior RT overlapping with fields
  5. Concurrent/prior invasive that could potentially interfere with proposed treatment. Individual cases can be discussed with PI prior to registration
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    BD + Intranasal Mupirocin + Chlorhexidine

    Bacterial Decolonization with 2% intranasal mupirocin ointment twice daily (BID) and 4% chlorhexidine gluconate body cleanser, once daily (QD) for 5 consecutive days prior to RT, and this will be repeated for 5 days every 2 weeks throughout Radiation Therapy. The treatment will also be administered for 5 consecutive days prior to index surgery. RT can be prescribed in one of three dose/fractionation regimens at the investigator's discretion: 50 Gy in 25 fractions, 42.75 Gy in 15 fractions, or 36 Gy in 18 fractions

    Drug: 2% intranasal mupirocin ointment · Drug: 4% chlorhexidine gluconate body cleanser

Interventions

  • DrugMupirocinStudies of MupirocinMupirocin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.

  • DrugChlorhexidine gluconateStudies of Chlorhexidine gluconateChlorhexidine gluconate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Chlorhexidine Gluconate (CHG) Solution Antiseptic Skin Cleanser solution is a topical skin cleanser that keeps working after it is used. CHG is a strong antiseptic (liquid used to kill germs and bacteria) that lowers the risk of infection.

    Also known as: Hibiclens®

06

What researchers measure

Primary outcomes

  1. Incidence and type of acute major wound complications

    Incidence and type of acute major wound complications: One or more of the following events occurring within 4 months of index sarcoma surgery including: 1). A secondary operation under general or regional anesthesia for wound repair (debridement, operative drainage, and secondary wound closure including rotationplasty, free flaps, or skin grafts), 2). Wound management without secondary operation, such, An invasive procedure without general or regional anesthesia (such as aspiration of seroma), Readmission for wound care such as intravenous antibiotics, or Persistent deep packing for 120 days or longer.

    Time frame: Up to 24 months

Secondary outcomes

  1. 1-year Local control

    Local control is defined as the proportion of patients without clinical evidence of local recurrence. This will be reported as will a cumulative incidence curve of local failures, considering using death as a competing risk, using the cumulative incidence function method.

    Time frame: At 1 year

  2. 2-year Local control

    Local control is defined as the proportion of patients without clinical evidence of local recurrence. This will be reported as will a cumulative incidence curve of local failures, considering using death as a competing risk, using the cumulative incidence function method.

    Time frame: At 2 years

  3. Progression-free survival (PFS)

    Median number of months from start of treatment until the date of disease progression or death from any cause.

    Time frame: Up to 24 months

  4. Overall survival (OS)

    Median number of months from start of treatment until death from any cause.

    Time frame: Up to 24 months

  5. Musculoskeletal Tumour Society Score [MSTS]

    The MSTS is a patient questionnaire for assessing physical function after medical treatment, surgery, and physiotherapy in patients with malignant bone tumors in specific extremities. The MSTS questionnaire consists of six domains, each scored on a scale from 0 to 5, with a higher score indicating better function. The total score, ranging from 0 (maximum disability) to 30 (no impairment), can be transformed to a point scale of 0 to 100.

    Time frame: Up to 24 months

  6. Toronto Extremity Salvage Score [TESS]

    TESS represents the gold standard for assessing function after surgery for muscle and bone tumors, as it has been tested for validity and reliability, and extremity-specifically defines disability, handicap, change in physical function depending on the therapeutic intervention and the patient's need for an aid. The TESS questionnaire has both upper and lower extremity versions. Twenty-nine items are rated on a scale from one to five, with five representing normal activity. The result ranges from 0 to 100, with 100 being the best score.

    Time frame: Up to 24 months

  7. Adverse Events and Serious Adverse Events related to intervention(s)

    Adverse Events and Serious Adverse Events per CTCAE v5.0 that attributed to study intervention(s).

    Time frame: Up to 24 months

  8. Frequency of late toxicities

    Acute toxicities are defined as toxicity occurring during preoperative RT, after RT and prior to surgery, and within 90 days of index resection, assessed using CTCAE v5.0.

    Time frame: Up to 24 months

  9. Change in type of actual surgical closures

    Tabulation of the initial surgical closure intended, and the actual surgical closure used at the time of index resection. Descriptive statistics will be used to summarize these assessments.

    Time frame: At surgery

07

Study locations

1 site
  • UPMC Hillman Cancer Centers
    Pittsburgh, Pennsylvania 15232, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Dec 2, 2024
StartEst.
Sep 30, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Per the PI, this study is not proceeding due to funding and insufficient support.
changed Oct 26, 2026
Enrollment
31 (estimated)→0 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Withdrawn
    Why stopped Per the PI, this study is not proceeding due to funding and insufficient support.
    Enrollment 31 (estimated)→0 (actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06712433
Lead sponsor
Adam Olson
Collaborators
Pittsburgh Cure Sarcoma
Responsible party
Adam Olson (Assistant Professor, Radiation Oncology, University of Pittsburgh) — Sponsor-investigator
First posted
Dec 2, 2024
Start date
Sep 30, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Adam M Olson, MD
principal investigator · UPMC Hillman Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mupirocin · Chlorhexidine gluconate

Start the discussion